August 16, 2017
August 16, 2017
Aug. 16, 2017 — US FDA has granted two orphan drug designations (ODD) for T cell therapy products to Singapore-based biotech company, Lion TCR Pte Ltd, for the treatment of hepatocellular carcinoma (HCC). Lion TCR are developing two product candidates — HBV specific TCR redirected T cell therapies against HCC with transient mRNA and a longer lasting DNA transduction technologies.
HCC is the world’s third leading cause of death due to cancer and the second for China. Globally, 60% of HCC is a result of chronic hepatitis B infection, for the case of China, it is more than 90%. There are 780,000 new HCC cases reported annually, the general prognosis is poor with overall survival rates of 3-5%.
US FDA Orphan drug designations are granted to drugs and biologics intended for rare diseases that affect fewer than 200,000 people in the U.S., and provides incentives that may include tax credits trials and user fee waivers. For products that treat diseases or conditions which cannot be satisfactorily treated by available alternative drugs, FDA may grant in condition approval for marketing after product’s completion of phase II pivotal clinical trial. This designation also entitles Lion TCR to a seven-year period of marketing exclusivity in the U.S. upon issuance of the new drug license.
Lion TCR’s founder and CEO, Dr. Li Lietao commented, “Profiting from US FDA’s well established regulatory framework and the ODD grant of our HBV specific TCR-T cell products, we aim to develop the clinical program internationally under FDA IND covering multiple sites in US, Europe and Asia. It will significantly accelerate our product development and speed up the commercialization of our products to both US and Asian markets.” PR Newswire
Lion TCR Licenses and Duke-NUS Medical School ink an exclusive IP licensing agreement for Immunosuppressive Drug Resistant Anti-Cancer T-cells
Dr Wai Lu-En, Director of R&D, represented Lion TCR to share the latest developments to the Minister for Manpower and Second Minister for Trade and Industry Tan See Leng.
Scientific Founder, Prof Antonio Bertoletti Appointed in Cell and Gene Therapy Workgroup in Singapore
Lion TCR Announces Data Presentation for its lead T-cell product, LioCyx-M at EASL Digital Liver Cancer Summit 2021
HSA approval for Phase 1 IND clinical trial for Lion TCR’s lead product LioCyx-M to characterize changes in liver cancer tumor microenvironment
Lion TCR presents two abstracts of Phase 1 clinical trial data for lead product LioCyx-M at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Companion diagnostic assay for personalised immunotherapy for HBV-related liver cancer featured in A*STAR GIS website
Singapore’s first clinical trial approval for T cell engineered (TCR) immunotherapy for treatment of Liver cancer
Lion TCR receives US$ 20 million to fund its personalized T cell therapy clinical trials against Liver cancer
Scientific Founder, Prof. Antonio Bertoletti and Scientific Consultant, Dr Anthony Tanoto Tan of Lion TCR were awarded the SingHealth Duke-NUS Research Award 1st Prize 2018
US FDA grants Lion TCR two orphan drug designations of T cell therapy against Hepatocellular Carcinoma
New publication – Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient